Register with MSD Connect
✔ Sign up for events
✔ Access learning modules
✔ Receive cancer resources
✔ Access additional content
KEYTRUDA® (pembrolizumab) KEYNOTE-048 5-year data
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
PDF, 1.20 MB
Download the interactive PDF to learn about the 5-year exploratory long-term follow-up data from KEYNOTE-048.1
KEYTRUDA, as monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy, is indicated for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD-L1 with a CPS ≥ 1.2
KEYTRUDA is associated with immune-related adverse events, please refer to the Summary of Product Characteristics before prescribing.
More information about KEYTRUDA® (pembrolizumab) in first-line head and neck squamous cell carcinoma:
Supporting documentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website.
References
- Tahara M et al. Presented at ESMO 2022. September 9–13, 2022. Abstract 659MO.
- KEYTRUDA Summary of Product Characteristics.
